Bank of New York Mellon’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $64.4M | Buy |
1,899,912
+105,480
| +6% | +$3.51M | 0.01% | 918 |
|
|
2026
Q1 | $54M | Sell |
1,794,432
-37,310
| -2% | -$1.2M | 0.01% | 951 |
|
|
2025
Q4 | $57.2M | Buy |
1,831,742
+167,480
| +10% | +$4.13M | 0.01% | 918 |
|
|
2025
Q3 | $33.6M | Sell |
1,664,262
-18,575
| -1% | -$326K | 0.01% | 1245 |
|
|
2025
Q2 | $28.2M | Buy |
1,682,837
+73,141
| +5% | +$1.18M | 0.01% | 1332 |
|
|
2025
Q1 | $24.7M | Sell |
1,609,696
-11,648
| -0.7% | -$208K | ﹤0.01% | 1386 |
|
|
2024
Q4 | $35.7M | Buy |
1,621,344
+67,571
| +4% | +$1.23M | 0.01% | 1227 |
|
|
2024
Q3 | $28M | Sell |
1,553,773
-48,440
| -3% | -$848K | 0.01% | 1382 |
|
|
2024
Q2 | $26M | Sell |
1,602,213
-33,055
| -2% | -$509K | ﹤0.01% | 1425 |
|
|
2024
Q1 | $23.1M | Sell |
1,635,268
-229,607
| -12% | -$2.89M | ﹤0.01% | 1494 |
|
|
2023
Q4 | $19.5M | Sell |
1,864,875
-37,360
| -2% | -$349K | ﹤0.01% | 1607 |
|
|
2023
Q3 | $19.4M | Buy |
1,902,235
+19,906
| +1% | +$185K | ﹤0.01% | 1558 |
|
|
2023
Q2 | $14.2M | Buy |
1,882,329
+76,961
| +4% | +$624K | ﹤0.01% | 1757 |
|
|
2023
Q1 | $16M | Sell |
1,805,368
-60,399
| -3% | -$597K | ﹤0.01% | 1672 |
|
|
2022
Q4 | $17M | Buy |
1,865,767
+9,834
| +0.5% | +$85.8K | ﹤0.01% | 1622 |
|
|
2022
Q3 | $15M | Buy |
1,855,933
+14,876
| +0.8% | +$132K | ﹤0.01% | 1666 |
|
|
2022
Q2 | $13.8M | Sell |
1,841,057
-34,337
| -2% | -$299K | ﹤0.01% | 1749 |
|
|
2022
Q1 | $17.6M | Buy |
1,875,394
+28,920
| +2% | +$241K | ﹤0.01% | 1746 |
|
|
2021
Q4 | $14.8M | Buy |
1,846,474
+53,274
| +3% | +$481K | ﹤0.01% | 1894 |
|
|
2021
Q3 | $17.5M | Buy |
1,793,200
+32,617
| +2% | +$305K | ﹤0.01% | 1801 |
|
|
2021
Q2 | $17.4M | Sell |
1,760,583
-182,087
| -9% | -$1.93M | ﹤0.01% | 1810 |
|
|
2021
Q1 | $22.4M | Sell |
1,942,670
-55,257
| -3% | -$634K | ﹤0.01% | 1645 |
|
|
2020
Q4 | $19.3M | Sell |
1,997,927
-16,700
| -0.8% | -$160K | ﹤0.01% | 1659 |
|
|
2020
Q3 | $18.2M | Sell |
2,014,627
-2,566
| -0.1% | -$27.1K | ﹤0.01% | 1536 |
|
|
2020
Q2 | $24.9M | Buy |
2,017,193
+125,519
| +7% | +$1.42M | 0.01% | 1307 |
|
|
2020
Q1 | $17M | Sell |
1,891,674
-31,334
| -2% | -$321K | 0.01% | 1399 |
|
|
2019
Q4 | $18.8M | Sell |
1,923,008
-63,544
| -3% | -$567K | ﹤0.01% | 1608 |
|
|
2019
Q3 | $13.7M | Buy |
1,986,552
+30,732
| +2% | +$235K | ﹤0.01% | 1754 |
|
|
2019
Q2 | $18.1M | Buy |
1,955,820
+127,204
| +7% | +$1.53M | ﹤0.01% | 1620 |
|
|
2019
Q1 | $28.7M | Sell |
1,828,616
-146,422
| -7% | -$2.58M | 0.01% | 1324 |
|
|
2018
Q4 | $30.5M | Buy |
1,975,038
+67,168
| +4% | +$1.38M | 0.01% | 1204 |
|
|
2018
Q3 | $41.1M | Sell |
1,907,870
-41,730
| -2% | -$969K | 0.01% | 1157 |
|
|
2018
Q2 | $47.4M | Buy |
1,949,600
+4,763
| +0.2% | +$97.1K | 0.01% | 1049 |
|
|
2018
Q1 | $33.2M | Sell |
1,944,837
-156,817
| -7% | -$3.06M | 0.01% | 1238 |
|
|
2017
Q4 | $39.8M | Sell |
2,101,654
-12,818,671
| -86% | -$193M | 0.01% | 1137 |
|
|
2017
Q3 | $263M | Sell |
14,920,325
-3,314,205
| -18% | -$74.6M | 0.07% | 288 |
|
|
2017
Q2 | $606M | Sell |
18,234,530
-1,163,875
| -6% | -$36M | 0.17% | 118 |
|
|
2017
Q1 | $622M | Sell |
19,398,405
-316,909
| -2% | -$10.8M | 0.17% | 118 |
|
|
2016
Q4 | $715M | Buy |
19,715,314
+3,590,348
| +22% | +$143M | 0.21% | 99 |
|
|
2016
Q3 | $742M | Buy |
16,124,966
+1,256,324
| +8% | +$65.5M | 0.22% | 88 |
|
|
2016
Q2 | $747M | Buy |
14,868,642
+1,972,944
| +15% | +$105M | 0.23% | 89 |
|
|
2016
Q1 | $690M | Buy |
12,895,698
+3,756,401
| +41% | +$220M | 0.21% | 104 |
|
|
2015
Q4 | $600M | Buy |
9,139,297
+2,310,846
| +34% | +$143M | 0.18% | 116 |
|
|
2015
Q3 | $386M | Buy |
6,828,451
+1,604,114
| +31% | +$104M | 0.12% | 171 |
|
|
2015
Q2 | $309M | Sell |
5,224,337
-476,936
| -8% | -$29.4M | 0.09% | 248 |
|
|
2015
Q1 | $355M | Buy |
5,701,273
+434,246
| +8% | +$25.2M | 0.09% | 233 |
|
|
2014
Q4 | $303M | Sell |
5,267,027
-443,217
| -8% | -$24.7M | 0.08% | 276 |
|
|
2014
Q3 | $307M | Sell |
5,710,244
-2,499,722
| -30% | -$132M | 0.08% | 260 |
|
|
2014
Q2 | $430M | Sell |
8,209,966
-131,510
| -2% | -$6.72M | 0.12% | 182 |
|
|
2014
Q1 | $441M | Sell |
8,341,476
-336,824
| -4% | -$15.6M | 0.12% | 171 |
|
|
2013
Q4 | $348M | Buy |
8,678,300
+3,220,731
| +59% | +$127M | 0.1% | 214 |
|
|
2013
Q3 | $206M | Buy |
5,457,569
+143,447
| +3% | +$5.6M | 0.06% | 332 |
|
|
2013
Q2 | $208M | Buy |
+5,314,122
| New | +$207M | 0.07% | 312 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Bank of New York Mellon's TEVA Position: Q2 2026 in Review
Bank of New York Mellon increased its Teva Pharmaceuticals (TEVA) stake by 5.9% in Q2 2026, buying an estimated $3.51M and bringing the position to 1,899,912 shares worth $64.4M. The position accounts for 0.01% of the portfolio, ranked #918.
Bank of New York Mellon first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $747M in Q2 2016. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Bank of New York Mellon held 1,899,912 shares of Teva Pharmaceuticals worth $64.4M as of Q2 2026.
- Bank of New York Mellon bought 105,480 Teva Pharmaceuticals shares in Q2 2026, an estimated $3.51M.
- Teva Pharmaceuticals made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #918 holding.
- Bank of New York Mellon first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's Teva Pharmaceuticals position peaked at $747M in Q2 2016.
- 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.